Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2210529 | 0.88 | GCK (1.00) | GCKSMN1; SMN2 | |
| SCHEMBL15825272 | 0.85 | GCK (0.75) | GCKSMN1; SMN2 | |
| SCHEMBL15834259 | 0.84 | GCK (0.77) | GCKSMN1; SMN2 | |
| SCHEMBL20636980 | 0.82 | GCK (0.72) | GCKSMN1; SMN2 | |
| SCHEMBL15824949 | 0.82 | GCK (0.69) | GCKSMN1; SMN2 | |
| SCHEMBL15825270 | 0.81 | GCK (0.83) | GCKSMN1; SMN2 | |
| SCHEMBL15826059 | 0.81 | GCK (0.69) | GCKSMN1; SMN2 | |
| SCHEMBL15834255 | 0.81 | GCK (0.74) | GCKSMN1; SMN2 | |
| SCHEMBL2213370 | 0.81 | GCK (0.73) | GCKSMN1; SMN2 | |
| SCHEMBL15824159 | 0.80 | GCK (0.68) | GCKSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629362-B2 | 2-pyridine carboxamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-12-08 | — | — | US | disclosed |
| US-20060258701-A1 | Novel 2-pyridinecarboxamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258701-A1 | Novel 2-pyridinecarboxamide derivatives | GCKR, GCK, HK2 | GCK 2/4885SMN1; SMN2 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.